OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation

Bone

Volumn 39, Issue 4, 2006, Pages 706-715

  Tat, Steeve Kwan ^a,b   Padrines, Marc ^a,b   Theoleyre, Sandrine ^a,b   Couillaud Battaglia, Severine ^a,b   Heymann, Dominique ^a,b   Redini, Françoise ^a,b   Fortun, Yannick ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Département Génie Biologique IUT Angers   (France)

Author keywords

Bioavailability; Internalization; OPG; Osteoblasts; RANKL

Indexed keywords

CLATHRIN ASSEMBLY PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; SYNDECAN 1;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; INCUBATION TIME; INTERNALIZATION; LIGAND BINDING; LYSOSOME MEMBRANE; MOUSE; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; VALIDATION STUDY; WESTERN BLOTTING;

EID: 33748199511     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.03.016     Document Type: Article

References (51)

1. Koshla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
2. Theoleyre S., Wittrant Y., Kwan Tat S., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15 (2004) 457-475
3. Kwan Tat S., Padrines M., Theoleyre S., Heymann D., and Fortun Y. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15 (2004) 49-60
4. Ritchlin C.T., Haas-Slith S.A., Li P., Hicks D.G., and Schwarz E.M. Mechanism of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 111 (2003) 821-831
5. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163 (2003) 2021-2031
6. Micigami T., Ihara-Watanabe M., Yamazaki M., and Ozono K. Receptor activator of nuclear kappa B ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 61 (2001) 1637-1644
7. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
8. Nakashima T., Wanda T., and Penninger J.M. RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 15 (2003) 280-287
9. Honore P., Luger N.M., Sabino M.A., Schwei M.J., Rogers S.D., Mach D.B., et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6 (2000) 521-528
10. Akatsu T., Murakami T., Ono K., Nishikawa M., Tsuda E., Mochizuki S.I., et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23 (1998) 495-498
11. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63 (2003) 287-289
12. Yonou H., Kanomata N., Goya M., Kamijo T., Yokose T., Hasebe T., et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into non obese diabetic/severe combined immunodeficient mice. Cancer Res 63 (2003) 2096-2102
13. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 (2001) 348-360
14. Croucher P.I., Shipman C.M., Van Camp B., and Vanderkerken K. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 97 (2003) 818-824
15. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
16. Emery J.G., McDonnell P., Burke M.B., Deen K.C., Lyn S., Silverman C., et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273 (1998) 14363-14367
17. Holen I., Croucher P.I., Hamdy F.C., and Eaton C.L. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62 (2002) 1619-1623
18. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63 (2003) 912-916
19. Standal T., Seidel C., Hjertner O., Plesner T., Sanderson R.D., Waage A., et al. Osteoprotegerin is bound, internalized and degraded by multiple myeloma cells. Blood 100 (2002) 3002-3007
20. Damiens C., Fortun Y., Charrier C., Heymann D., and Padrines M. Modulation by soluble factors of gelatinase activities released by osteoblastic cells. Cytokine 12 (2000) 1727-1731
21. El Amin S.F., Attawia M., Lu H.H., Shah A.K., Chang R., Hickok N.J., et al. Integrin expression by human osteoblasts cultured on degradable polymeric materials applicable for tissue engineered bone. J Orthop Res 20 (2002) 20-28
22. Chipoy C., Berreur M., Couillaud S., Pradal G., Vallette F., Colombeix C., et al. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 19 (2004) 1850-1861
23. Jiang J., Nicoll S.B., and Lu H.H. Co-culture of osteoblasts and chondrocytes modulates cellular differentiation in vitro. Biochem Biophys Res Commun 338 (2005) 762-770
24. Tejedor F., and Ballesta J.P. Reaction of some macrolide antibiotics with the ribosome. Labeling of the binding site components. Biochemistry 25 (1986) 7725-7731
25. Godard A., Heymann D., Raher S., Anegon I., Peyrat M.A., Le Mauff B., et al. High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. Molecular characterization and cellular distribution. J Biol Chem 267 (1992) 3214-3222
26. Scatchard G. The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 57 (1949) 660-672
27. Closer J., and Gowen M. Are MG-63 and HOS TE85 human osteosarcoma cell lines representative models of the osteoblastic phenotype?. Bone 15 (1994) 585-591
28. Heymann D., Ory B., Gouin F., Green J.R., and Rédini F. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 10 (2004) 337-343
29. Pfister T., Atzpodien E., and Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 191 (2000) 159-167
30. Peter R., Mishra V., and Fraser W.D. Severe hypocalcemia after being given intravenous bisphosphonate. BMJ 328 (2004) 335-336
31. Whyte M.P., Wenkert D., Clements K.L., McAlister W.H., and Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med 349 (2003) 457-463
32. Wittrant Y., Théoleyre S., Chipoy C., Padrines M., Blanchard F., and Rédini F. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704 (2004) 49-57
33. Heymann D., Fortun Y., Rédini F., and Padrines M. Osteolytic bone diseases: physiological analogues of bone resorption effectors as alternative therapeutic tools. Drug Discov Today 10 (2005) 242-247
34. Tkachenko E., Lutgens E., Stan R.V., and Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci 117 (2004) 3189-3199
35. Llorente A., Prydk K., Sprangers M., Sktretting G., Kolset S.O., and Sandvig K. Proteoglycan synthesis is increased in cells with impaired clathrin-dependent endocytosis. J Cell Sci 114 (2001) 335-343
36. Anderson M.A., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
37. Lee Z.H., and Kim H.H. Signal transduction by receptor of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305 (2003) 211-214
38. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
39. D'Alessio A., Al-Lamki R.S., Bradley J.R., and Pober J.S. Caveolae participate in tumor necrosis factor receptor 1 signaling and internalization in human endothelial cell line. Am J Pathol 166 (2005) 1273-1282
40. Ha H., Kwak H.B., Lee S.K., Na D.S., Rudd C.E., Lee Z.H., et al. Membrane rafts play a crucial role in receptor activator of nuclear factor κB signaling and osteoclast function. J Biol Chem 278 (2003) 18573-18580
41. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Brugess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
42. Horowitz M.C., Xi Y., Wilson K., and Kacena M.A. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12 (2001) 9-18
43. Lethi K., Valtanen H., Wickstrom S., Lohi J., and Keski-Oja J. Regulation of membrane-type-1 matrix metalloproteinase activity by 1st cytoplasmic domain. J Biol Chem 275 (2000) 15006-15013
44. Jiang A., Lethi K., Wang X., Weiss S.J., Keski-Oja J., and Pei D. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc Natl Acad Sci U S A 98 (2001) 13693-13698
45. Uekita T., Itoh Y., Yana I., Ohno H., and Seiki M. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J Cell Biol 155 (2001) 1345-1356
46. Remacle A., Murphy G., and Roghi C. Membrane type 1 matrix metalloproteinase (MT1-MMP) is internalized by two different pathways and recycled to the cell surface. J Cell Sci 116 (2003) 3905-3916
47. Maquoi E., Frankenne F., Baramova E., Munaut C., Sounni N.E., Remacle A., et al. Membrane type matrix metalloproteinase-associated degradation of tissue inhibitor of metalloproteinase 2 in human tumor cell line. J Biol Chem 275 (2000) 11368-11378
48. Capparelli C., Kostenuik P.J., Morony S., Starnes C., Weimann B., Van G., et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60 (2000) 783-787
49. Romas E., Sims N.A., Hards D.K., Lindsay M., Quinn J.W., Ryan P.F., et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 161 (2002) 1419-1427
50. Takayanagi H., Lizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor kappa B ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43 (2000) 259-269
51. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single dose controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in posmenopausal women. J Bone Miner Res 19 (2004) 1059-1066